Empagliflozin in heart failure with a preserved ejection fraction
Abstract: Background: Sodium–glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, but their effects in patients with heart failure and a preserved ejection fraction are uncertain. Methods: In thi...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Artículo |
| Lenguaje: | Inglés |
| Publicado: |
Eric J. Rubin
2024
|
| Materias: | |
| Acceso en línea: | https://repositorio.uca.edu.ar/handle/123456789/18056 |
| Aporte de: |
| id |
I33-R139-123456789-18056 |
|---|---|
| record_format |
dspace |
| spelling |
I33-R139-123456789-180562025-02-12T14:14:35Z Empagliflozin in heart failure with a preserved ejection fraction Anker, Stefan D. Butler, Javed Filippatos, Gerasimos Ferreira, João P. Bocchi, Edimar Böhm, Michael Brunner-La Rocca, Hans-Peter DongJu, Choi Chopra, Vijay Chuquiure Valenzuela, Eduardo Giannetti, Nadia Gómez Mesa, Juan Esteban Janssens, Stefan Januzzi, James L. González Juanatey, Jose Ramón Merkely, Bela Nicholls, Stephen J. Perrone, Sergio Piña, Ileana L. Ponikowski, Piotr Senni, Michele Sim, David Spinar, Jindrich Squire, Iain Taddei, Stefano Tsutsui, Hiroyuki Verma, Subodh Vinereanu, Dragos Zhang, Jian Carson, Peter Lam Su Ping, Carolyn Zeller, Cordula Sattar, Naveed Jamal, Waheed Schnaidt, Sven Schnee, Janet M. Brueckmann, Martina Pocock, Stuart J. Zannad, Faiez Packer, Milton INSUFICIENCIA CARDIACA INHIBIDOR SODIO-GLUCOSA 2 EMPAGLIFLOZINA MEDICINA Abstract: Background: Sodium–glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, but their effects in patients with heart failure and a preserved ejection fraction are uncertain. Methods: In this double-blind trial, we randomly assigned 5988 patients with class II–IV heart failure and an ejection fraction of more than 40% to receive empagliflozin (10 mg once daily) or placebo, in addition to usual therapy. The primary outcome was a composite of cardiovascular death or hospitalization for heart failure. Results: Over a median of 26.2 months, a primary outcome event occurred in 415 of 2997 patients (13.8%) in the empagliflozin group and in 511 of 2991 patients (17.1%) in the placebo group (hazard ratio, 0.79; 95% confidence interval [CI], 0.69 to 0.90; P<0.001). This effect was mainly related to a lower risk of hospitalization for heart failure in the empagliflozin group. The effects of empagliflozin appeared consistent in patients with or without diabetes. The total number of hospitalizations for heart failure was lower in the empagliflozin group than in the placebo group (407 with empagliflozin and 541 with placebo; hazard ratio, 0.73; 95% CI, 0.61 to 0.88; P<0.001). Uncomplicated genital and urinary tract infections and hypotension were reported more frequently with empagliflozin. 2024-05-07T16:57:57Z 2024-05-07T16:57:57Z 2021 Artículo Anker, S. D., Butler, J. et al. Empagliflozin in heart failure with a preserved ejection fraction [en línea]. New England Journal of Medicine. 2021, 385 (16). doi: 10.1056/NEJMoa2107038. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/18056 1533-4406 (online) 0028-4793 (impreso) https://repositorio.uca.edu.ar/handle/123456789/18056 10.1056/NEJMoa2107038 34449189 eng Acceso abierto http://creativecommons.org/licenses/by-nc-sa/4.0/ application/pdf Eric J. Rubin New England Journal of Medicine. 2021, 385 (16) |
| institution |
Universidad Católica Argentina |
| institution_str |
I-33 |
| repository_str |
R-139 |
| collection |
Repositorio Institucional de la Universidad Católica Argentina (UCA) |
| language |
Inglés |
| topic |
INSUFICIENCIA CARDIACA INHIBIDOR SODIO-GLUCOSA 2 EMPAGLIFLOZINA MEDICINA |
| spellingShingle |
INSUFICIENCIA CARDIACA INHIBIDOR SODIO-GLUCOSA 2 EMPAGLIFLOZINA MEDICINA Anker, Stefan D. Butler, Javed Filippatos, Gerasimos Ferreira, João P. Bocchi, Edimar Böhm, Michael Brunner-La Rocca, Hans-Peter DongJu, Choi Chopra, Vijay Chuquiure Valenzuela, Eduardo Giannetti, Nadia Gómez Mesa, Juan Esteban Janssens, Stefan Januzzi, James L. González Juanatey, Jose Ramón Merkely, Bela Nicholls, Stephen J. Perrone, Sergio Piña, Ileana L. Ponikowski, Piotr Senni, Michele Sim, David Spinar, Jindrich Squire, Iain Taddei, Stefano Tsutsui, Hiroyuki Verma, Subodh Vinereanu, Dragos Zhang, Jian Carson, Peter Lam Su Ping, Carolyn Zeller, Cordula Sattar, Naveed Jamal, Waheed Schnaidt, Sven Schnee, Janet M. Brueckmann, Martina Pocock, Stuart J. Zannad, Faiez Packer, Milton Empagliflozin in heart failure with a preserved ejection fraction |
| topic_facet |
INSUFICIENCIA CARDIACA INHIBIDOR SODIO-GLUCOSA 2 EMPAGLIFLOZINA MEDICINA |
| description |
Abstract: Background: Sodium–glucose cotransporter 2 inhibitors reduce the risk of hospitalization for
heart failure in patients with heart failure and a reduced ejection fraction, but
their effects in patients with heart failure and a preserved ejection fraction are
uncertain.
Methods:
In this double-blind trial, we randomly assigned 5988 patients with class II–IV
heart failure and an ejection fraction of more than 40% to receive empagliflozin
(10 mg once daily) or placebo, in addition to usual therapy. The primary outcome
was a composite of cardiovascular death or hospitalization for heart failure.
Results:
Over a median of 26.2 months, a primary outcome event occurred in 415 of 2997
patients (13.8%) in the empagliflozin group and in 511 of 2991 patients (17.1%) in
the placebo group (hazard ratio, 0.79; 95% confidence interval [CI], 0.69 to 0.90;
P<0.001). This effect was mainly related to a lower risk of hospitalization for heart
failure in the empagliflozin group. The effects of empagliflozin appeared consistent
in patients with or without diabetes. The total number of hospitalizations for
heart failure was lower in the empagliflozin group than in the placebo group (407
with empagliflozin and 541 with placebo; hazard ratio, 0.73; 95% CI, 0.61 to 0.88;
P<0.001). Uncomplicated genital and urinary tract infections and hypotension were
reported more frequently with empagliflozin. |
| format |
Artículo |
| author |
Anker, Stefan D. Butler, Javed Filippatos, Gerasimos Ferreira, João P. Bocchi, Edimar Böhm, Michael Brunner-La Rocca, Hans-Peter DongJu, Choi Chopra, Vijay Chuquiure Valenzuela, Eduardo Giannetti, Nadia Gómez Mesa, Juan Esteban Janssens, Stefan Januzzi, James L. González Juanatey, Jose Ramón Merkely, Bela Nicholls, Stephen J. Perrone, Sergio Piña, Ileana L. Ponikowski, Piotr Senni, Michele Sim, David Spinar, Jindrich Squire, Iain Taddei, Stefano Tsutsui, Hiroyuki Verma, Subodh Vinereanu, Dragos Zhang, Jian Carson, Peter Lam Su Ping, Carolyn Zeller, Cordula Sattar, Naveed Jamal, Waheed Schnaidt, Sven Schnee, Janet M. Brueckmann, Martina Pocock, Stuart J. Zannad, Faiez Packer, Milton |
| author_facet |
Anker, Stefan D. Butler, Javed Filippatos, Gerasimos Ferreira, João P. Bocchi, Edimar Böhm, Michael Brunner-La Rocca, Hans-Peter DongJu, Choi Chopra, Vijay Chuquiure Valenzuela, Eduardo Giannetti, Nadia Gómez Mesa, Juan Esteban Janssens, Stefan Januzzi, James L. González Juanatey, Jose Ramón Merkely, Bela Nicholls, Stephen J. Perrone, Sergio Piña, Ileana L. Ponikowski, Piotr Senni, Michele Sim, David Spinar, Jindrich Squire, Iain Taddei, Stefano Tsutsui, Hiroyuki Verma, Subodh Vinereanu, Dragos Zhang, Jian Carson, Peter Lam Su Ping, Carolyn Zeller, Cordula Sattar, Naveed Jamal, Waheed Schnaidt, Sven Schnee, Janet M. Brueckmann, Martina Pocock, Stuart J. Zannad, Faiez Packer, Milton |
| author_sort |
Anker, Stefan D. |
| title |
Empagliflozin in heart failure with a preserved ejection fraction |
| title_short |
Empagliflozin in heart failure with a preserved ejection fraction |
| title_full |
Empagliflozin in heart failure with a preserved ejection fraction |
| title_fullStr |
Empagliflozin in heart failure with a preserved ejection fraction |
| title_full_unstemmed |
Empagliflozin in heart failure with a preserved ejection fraction |
| title_sort |
empagliflozin in heart failure with a preserved ejection fraction |
| publisher |
Eric J. Rubin |
| publishDate |
2024 |
| url |
https://repositorio.uca.edu.ar/handle/123456789/18056 |
| work_keys_str_mv |
AT ankerstefand empagliflozininheartfailurewithapreservedejectionfraction AT butlerjaved empagliflozininheartfailurewithapreservedejectionfraction AT filippatosgerasimos empagliflozininheartfailurewithapreservedejectionfraction AT ferreirajoaop empagliflozininheartfailurewithapreservedejectionfraction AT bocchiedimar empagliflozininheartfailurewithapreservedejectionfraction AT bohmmichael empagliflozininheartfailurewithapreservedejectionfraction AT brunnerlaroccahanspeter empagliflozininheartfailurewithapreservedejectionfraction AT dongjuchoi empagliflozininheartfailurewithapreservedejectionfraction AT chopravijay empagliflozininheartfailurewithapreservedejectionfraction AT chuquiurevalenzuelaeduardo empagliflozininheartfailurewithapreservedejectionfraction AT giannettinadia empagliflozininheartfailurewithapreservedejectionfraction AT gomezmesajuanesteban empagliflozininheartfailurewithapreservedejectionfraction AT janssensstefan empagliflozininheartfailurewithapreservedejectionfraction AT januzzijamesl empagliflozininheartfailurewithapreservedejectionfraction AT gonzalezjuanateyjoseramon empagliflozininheartfailurewithapreservedejectionfraction AT merkelybela empagliflozininheartfailurewithapreservedejectionfraction AT nichollsstephenj empagliflozininheartfailurewithapreservedejectionfraction AT perronesergio empagliflozininheartfailurewithapreservedejectionfraction AT pinaileanal empagliflozininheartfailurewithapreservedejectionfraction AT ponikowskipiotr empagliflozininheartfailurewithapreservedejectionfraction AT sennimichele empagliflozininheartfailurewithapreservedejectionfraction AT simdavid empagliflozininheartfailurewithapreservedejectionfraction AT spinarjindrich empagliflozininheartfailurewithapreservedejectionfraction AT squireiain empagliflozininheartfailurewithapreservedejectionfraction AT taddeistefano empagliflozininheartfailurewithapreservedejectionfraction AT tsutsuihiroyuki empagliflozininheartfailurewithapreservedejectionfraction AT vermasubodh empagliflozininheartfailurewithapreservedejectionfraction AT vinereanudragos empagliflozininheartfailurewithapreservedejectionfraction AT zhangjian empagliflozininheartfailurewithapreservedejectionfraction AT carsonpeter empagliflozininheartfailurewithapreservedejectionfraction AT lamsupingcarolyn empagliflozininheartfailurewithapreservedejectionfraction AT zellercordula empagliflozininheartfailurewithapreservedejectionfraction AT sattarnaveed empagliflozininheartfailurewithapreservedejectionfraction AT jamalwaheed empagliflozininheartfailurewithapreservedejectionfraction AT schnaidtsven empagliflozininheartfailurewithapreservedejectionfraction AT schneejanetm empagliflozininheartfailurewithapreservedejectionfraction AT brueckmannmartina empagliflozininheartfailurewithapreservedejectionfraction AT pocockstuartj empagliflozininheartfailurewithapreservedejectionfraction AT zannadfaiez empagliflozininheartfailurewithapreservedejectionfraction AT packermilton empagliflozininheartfailurewithapreservedejectionfraction |
| _version_ |
1824348101229412352 |